Novo Holdings eyes opportunities as biotech bubble bursts
After years of speculation and premature IPOs, the biotech bubble has burst, says CEO of Novo Holdings Kasim Kutay, who’s now fishing in the troubled waters, saying that the downswing might not last.
by ANDREAS LØNSTRUP, translated by daniel pedersen
In 2021, Novo Holdings could once again report that few life science players are better at making money than the holding company itself, which booked a total income of EUR 5bn in 2021.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
